Robotic, Open Cystectomy Outcomes Similar

5-year recurrence-free and cancer-specific survival rates with RARC are 52.5% and 67.8%.
5-year recurrence-free and cancer-specific survival rates with RARC are 52.5% and 67.8%.

Five-year survival rates after robot-assisted radical cystectomy (RARC) are similar to those previously reported for open radical cystectomy, investigators reported.

A team Roswell Park Cancer Institute in Buffalo, N.Y., led by Khurshid A. Guru, MD, reviewed long-term oncologic outcomes in 99 patients who underwent RARC for bladder cancer. The median follow-up was 30.9 months. The 40 patients (41%) who were alive for more than 60 months had a median follow-up of 73.9 months. The 5-year recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) rates were 52.5%, 67.8%, and 42.4%, respectively, Dr. Guru's group reported online ahead of print in European Urology.

On multivariable analysis, higher pT stage and pN stage independently predicted worse RFS, CSS, and OS, whereas positive surgical margins and Charlson comorbidity index predicted only CSS and OS.

Loading links....
You must be a registered member of Renal and Urology News to post a comment.